- Home
- BYSI
BYSI
BeyondSpring Inc.
as of 03-02-2026 3:53pm EST
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 58.4M | IPO Year: | 2016 |
| Target Price: | N/A | AVG Volume (30 days): | 20.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.98 - $3.44 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -45.00 | Index: | N/A |
| Free Cash Flow: | -16667000.0 | FCF Growth: | N/A |
Compare BYSI vs Leading Stocks
See how BYSI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BYSI BeyondSpring Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.